The content of matrix metalloproteinase-12 in pregnancy complicated by preeclampsia

Abstract

Relevance. Pre-eclampsia is the most difficult and important problem in obstetrics, it ranks third in the structure of maternal mortality. Until now, there is no single idea of the mechanisms of development of this pathological process. The study of the concentration of MMP-12 in pregnancy will determine its possible role in the development of pre-eclampsia.

Aim. Сompare the dynamics of the concentration of matrix metalloproteinase-12 (MMP-12) in pregnancy complicated and not complicated by preeclampsia.

Materials and methods. A prospective study of two groups of women: the main group is pregnant (n = 17) with preeclampsia (moderate (n = 11) and severe (n = 6)), the comparison group is women whose pregnancy was not complicated by preeclampsia (n = 83). The concentration of matrix metalloproteinase-12 was determined by the method of enzyme immunoassay in serum at 11-13, 22-24, 32-34 weeks of gestation.

Results. In the group of pregnant women without preeclampsia, there was a sharp decrease in the concentration of MMP-12 from the I trimester to II (p = 0.0001), followed by a slight increase to the III trimester. In the group of pregnant women with preeclampsia, an increase in the concentration from the I trimester to II (p = 0.0001) was established. A significant difference in the concentration of MMP-12 between groups in the first trimester of pregnancy was shown (p = 0.0001).

Conclusion. Thus, the results of the study indicate the role of MMP-12 in the initial stages of placentation.

Keywords

preeclampsia / matrix metalloproteinases / matrix metalloproteinase-12 / pathogenesis of preeclampsia / biomarkers / implantation

References

[1] 1.Say L, Chou D, Gemmill A, et al. Global Causes of Maternal Death: A WHO sytematic Analysis. Lancet Global Health. 2014;2(6):323-33. doi:10.1016/S2214-109X(14)70227-X.

[2] 2.Айламазян Э.К., Репина М.А. Комментарии к клиническому протоколу «Гипертензия во время беременности, преэклампсия, эклампсия» // Журнал акушерства и женских болезней. – 2012. – Т. 61. – № 5. – С. 3–9. [Aylamazyan EK, Repina MA. The usual comment to clinical protocol “Hypertension during pregnancy, preeclampsia, eclampsia”. Journal of Obstetrics and Women’s Diseases. 2012;61(5):3-9. (In Russ.)]

[3] 3.Соколов Д.И. Васкулогенез и ангиогенез в развитии плаценты // Журнал акушерства и женских болезней. – 2007. – Т. 56. – № 3. – С. 129–133. [Sokolov DI. Vasculogenesis and angiogenesis in development of a placenta. Journal of Obstetrics and Women’s Diseases.2007;56(3):129-33. (In Russ.)]

[4] 4.Мозговая Е.В., Постникова Т.Б., Аржанова О.Н., и др. Выявление риска развития гестоза (преэклампсии) и оценка эффективности его профилактики с помощью неинвазивного метода исследования функции эндотелия // Журнал акушерства и женских болезней. – 2015. – T. 64. – № 3. – С. 58–68. [Mozgovaya EV, Postnikova TB, Arzhanova ON, Repinskaya EA, et al. Identification of gestosis (preeclampsia) risk and evaluation of efficiency of its prevention by means of noninvasive measurement of endothelial function. Journal of Obstetrics and Women’s Diseases. 2015;64(3):58-68. (In Russ.)]

[5] 5.Ишкараева В.В., Яковлева Н.Ю., Зазерская И.Е. Нарушение функционирования трофобласта, как пусковой фактор развития преэклампсии // Трансляционная медицина: сборник работ. – СПб., 2015. – C. 709–717. [Ishkaraeva VV, Yakovleva NYu, Zazerskaya IE. Narushenie funkcionirovanija trofoblasta, kak puskovoj faktor razvitija prejeklampsii. In: Transljacionnaja medicina: sbornik. Saint Petersburg; 2015. P. 709-17. (In Russ.)]

[6] 6.Яковлева Н.Ю., Хазова Е.Л., Васильева Е.Ю., Зазерская И.Е. Соотношение ангиогенных и антиангиогенного факторов при преэклампсии // Арте риальная гипертензия. – 2016. – Т. 22. – № 5. – С. 488–494. [Yakovleva NYu, Khazova EL, Vasil’eva EYu, Zazerskaya IE. Ratio of angiogenicand anti-angiogenic factors in preeclampsia. Arterial’naja gipertenzija. 2016;22(5):488-94. (In Russ.)]. doi: 10.18705/1607-419X-2016-22-5-488-494.

[7] 7.Рябоконь Н.Р., Зазерская И.Е., Большакова О.О. Особенности жесткости сосудов при преэклампсии и после родов // Журнал акушерства и женских болезней. – 2016. – Т. 65. – № 5. – С. 49–55. [Ria bokon NR, Zazerskaya IE, Bolshakova OO. Features of vascular stiffness in pregnancy complicated by preeclampsia and postpartum. Journal of Obstetrics and Women’s Diseases. 2016;65(5):49-55. (In Russ.)]. doi: 10.17816/JOWD65549-55.

[8] 8.Hulboy DL, Rudolph LA, Matrisian LM. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod. 1997;3:27-45. doi: org/10.1093/molehr/3.1.27.

[9] 9.Hamid JAb. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and 2 as potential biomarkers for gestational hypertension. Singapore Med J. 2012;53(10):681-683.

[10] 10.Montagnana M, Mohtarrudin N, Osman M, et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009;23(2):88-92. doi: 10.1002/jcla.20295.

[11] 11.Seval Y, Akkoyunlu G, Demir R, Asar M. Distribution patterns of matrix metalloproteinase (MMP)-2 and -9 and their inhibitors (TIMP-1 and TIMP-2) in the human decidua during early pregnancy. Acta Histochem. 2004;106(5):353-62. doi: 10.1016/j.acthis.2004.07.005.

[12] 12.Anacker J, Feix S, Kapp M, et al. Expression pattern of matrix metalloproteinases (MMPs) in human decidua during pregnancy. Journal of Reproductive Immunology. 2010;86:79-111. doi: 10.1016/j.jri.2010.08.002.

[13] 13.Jia Yu Zhu, Mei Zhong, Zhan Jun Pang, Yan Hong Yu. Dysregulated expression of matrix metalloproteinases and their inhibitors may participate in the pathogenesis of pre-eclampsia and fetal growth restriction. Early Human Development. 2014;90:657-64. doi: 10.1016/j.earlhumdev.2014.08.007.

[14] 14.Harris LK, Smith SD, Keogh RJ, et al. Trophoblast- and Vascular Smooth Muscle Cell-Derived MMP-12 Mediates Elastolysis during Uterine Spiral Artery Remodeling. The American Journal of Pathology. 2010;177(4);2103-15. doi: 10.2353/ajpath.2010.100182.

[15] 15.Стрюк Р.И., Бакалов С.А., Бунин Ю.А., и др. Диагностика и лечение сердечно-сосудистых заболеваний при беременности. Российские рекомендации // Российский кардиологический журнал. – 2013. – № 4 S1(102). – С. 1–40. [Strjuk RI, Bakalov SA, Bunin JuA, et al. Diagnostika i lechenie serdechno-sosudistyh zabolevanij pri beremennosti. Rossijskie rekomendacii. Rossijskij kardiologicheskij zhurnal. 2013;(4 S1(102)):1-40. (In Russ.)]

[16] 16.Клишо Е.В. Кондакова И.В. Чойнзонов Е.Л. Матриксные металлопротеиназы в онкогенезе // Сибирский онкологический журнал. – 2003. – № 2. – С. 63–70. [Klisho EV, Kondakova IV, Chojnzonov EL. Matriksnye metalloproteinazy v onkogeneze. Sibirskij onkologicheskij zhurnal. 2003;(2):63-70. (In Russ.)]

[17] 17.Amalinei C, Romanian J. Matrix metalloproteinases involvement in pathologic conditions. Morphology Embriology. 2010;51(2):215-28.

[18] 18.Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. The FASEB Journal. 1991;5(8):2145-54.

[19] 19.Hulboy DL, Rudolph LA, Matrisian LM. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod. 1997;3:27-45. doi: 10.1093/molehr/3.1.27.

[20] 20.Firestein GS, Gabriel SE, McInnes IB, O’Dell JR. Kelley and Firestein’s textbook of rheumatology. 10th edition. NY; 2013.

[21] 21.Founds SA, Conley YP, Lyons-Weiler JF, et al. Altered global gene expression in first-trimester placentas of women destined to develop preeclampsia. Placenta. 2009;30:15-24. doi: 10.1016/j.placenta.2008.09.015.

RIGHTS & PERMISSIONS

Yakovleva N.Y., Vasileva E.Y., Kuznetsova L.V., Shelepova E.S., Khazova E.L., Repinskaya E.A.